Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MER3101
- Development stage
- Phase 1
- Lead developer
- Mercia Pharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
MER3101 is an investigational antigen-specific immunotherapeutic (ASI) vaccine developed for the prevention and treatment of Type 1 Diabetes (T1D). It consists of the insulin B chain (IBC) as the primary autoantigen, formulated with MAS-1, a proprietary nanoparticular, emulsion-based adjuvant. The therapy is designed to restore immune tolerance by shifting the immune response from a destructive pro-inflammatory Th1/Th17 profile toward a protective Th2 and regulatory T cell (Treg) response. Preclinical studies in NOD mice demonstrated that MER3101 induces the expansion of insulin-specific Tr1 and FoxP3+ regulatory T cells and increases the secretion of anti-inflammatory cytokines such as IL-10, IL-4, and IL-5. MER3101 is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and ability to preserve beta-cell function in patients with recently diagnosed T1D by favoring tolerogenic pathways to reverse autoimmunity.
- Other names
- MAS-1 adjuvanted Insulin B-chainMAS1 adjuvanted Insulin B-chainMAS 1 adjuvanted Insulin B-chainMAS-1 adjuvanted IBCMAS1 adjuvanted IBCMAS 1 adjuvanted IBC
02
Targets
MHC II (Major histocompatibility complex class II receptor)TCR–MHC II (TCR–MHC class II complex)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on MER3101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MER3101.